Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the 10 Stocks Entering June in the Wrong Direction. Summit Therapeutics ...

New ASCO data boosted the case for Ivonescimab as a potential challenger to Merck's blockbuster cancer drug Keytruda. ・Phase ...

Shares of Summit Therapeutics PLC (SMMT) have gained 8.8% over the past four weeks to close the last trading session at ...

Summit Therapeutics Inc. (NASDAQ:SMMT) ranks among the best short squeeze stocks to invest in. On May 22, Cantor Fitzgerald ...

Summit Therapeutics advances ivonescimab with late-stage NSCLC and CRC studies, with FDA review underway and new partnerships ...

Fintel reports that on March 26, 2025, Citigroup upgraded their outlook for Summit Therapeutics (NasdaqGM:SMMT) from Neutral to Buy. As of March 18, 2025, the average one-year price target for Summit ...

Summit Therapeutics (SMMT) stock faced a downgrade at H.C. Wainwright after late-stage trial data for Merck’s (MRK) lung cancer drug sac-TMT. Read more here.

Summit Therapeutics (NASDAQ: SMMT) experienced a significant 30% decrease in its stock on Friday, May 30th, closing at $18. This sudden decline came even though the stock had doubled within the past ...

In recent trading, shares of Summit Therapeutics Inc (Symbol: SMMT) have crossed above the average analyst 12-month target price of $35.57, changing hands for $36.70/share. When a stock reaches the ...

Bronte Capital, an investment management company, released its “Amalthea Fund” third-quarter 2024 investor letter. A copy of the letter can be downloaded here ...

We recently published a list of These 10 Stocks Just Rocked The Market. In this article, we are going to take a look at where Summit Therapeutics Inc. (NASDAQ:SMMT) stands against other stocks that ...